Stephanie N. Bass

Stephanie N. Bass

Auto-generated profile, based on publicly available information

Stephanie N. Bass

Department of Pharmacy, Cleveland Clinic, OH, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2023 in Chest
Verified
Journal Article
Closed access
JYJason R. Yerke
Jason R. Yerke
EMEduardo Mireles-Cabodevila
Eduardo Mireles-Cabodevila
ACAlyssa Y. Chen
Alyssa Y. Chen
SBStephanie N. Bass
Stephanie N. Bass
ARAnita J. Reddy
Anita J. Reddy
AMAjit Moghekar
Ajit Moghekar

27 August 2026 in Annals of Pharmacotherapy
Verified
Journal Article
Open access
TPTien Q. Pham
Tien Q. Pham
JYJason R. Yerke
Jason R. Yerke
MRMichael A. Rudoni
Michael A. Rudoni
CLChristina C. Lindenmeyer
Christina C. Lindenmeyer
AKAanchal Kapoor
Aanchal Kapoor
SBStephanie N. Bass
Stephanie N. Bass
Background: In acute variceal hemorrhage (AVH), guidelines recommend 2 to 5 days of octreotide following endoscopic hemostasis to reduce early rebleeding; however, the optimal duration of therapy remains undefined. Objective: To evaluate whether a shorter duration of octreotide therapy is non-inferior to a longer duration in preventing early rebleeding and adverse clinical outcomes. Methods: This multicenter, retrospective non-inferiority study included adults with cirrhosis and endoscopically confirmed AVH admitted to 13 hospitals within the Cleveland Clinic Health System between January 2020 and August 2024. Patients were categorized by post-endoscopic octreotide infusion duration: short-course (≤72 h) or long-course (>72 h). The primary outcome was 5-day rebleeding, with a prespecified non-inferiority margin of 15%. Secondary outcomes included 48-hour rebleeding, transfusion requirements, in-hospital mortality, adverse events, and octreotide-related costs. Results: Among 260 patients, 131 received short-course and 129 received long-course octreotide therapy. Rebleeding within 5 days occurred in 27.5% and 31.0% of patients, respectively (absolute risk difference = −3.5%; 95% confidence interval = −14.6% to 7.5%), meeting the non-inferiority threshold. Secondary outcomes were similar: 48-hour rebleeding (17.6% vs 20.2%), median blood transfusion (0 vs 0 units), and in-hospital mortality (10.7% vs 18.6%). Rates of bradycardia, hypo- or hyperglycemia, and ileus did not differ. Octreotide-related treatment costs were significantly lower in the short-course group. Conclusion and Relevance: In patients with AVH who achieved endoscopic hemostasis, short-course octreotide therapy was non-inferior to longer-course therapy in preventing early rebleeding, with similar clinical outcomes and lower treatment cost.

28 November 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
TPTien Q. Pham
Tien Q. Pham
SBStephanie N. Bass
Stephanie N. Bass
JYJason R. Yerke
Jason R. Yerke

12 November 2026 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
ZMZineb Moustaatif
Zineb Moustaatif
AKAanchal Kapoor
Aanchal Kapoor
JYJason R. Yerke
Jason R. Yerke
SBStephanie Bass
Stephanie Bass
SDSiddharth Dugar
Siddharth Dugar
Background: Calcium channel blocker (CCB) overdose is a significant cause of cardiovascular drug overdose-related mortality, with amlodipine emerging as the most frequently implicated agent in serious intoxication. Current management strategies for CCB poisoning include vasopressors, high-dose insulin therapy, and other adjunctive treatments. The unique pharmacodynamic profile of amlodipine can lead to severe and persistent vasoplegic shock that is refractory to conventional therapy. The Molecular Adsorbent Recirculating System (MARS), an albumin dialysis technique capable of removing protein-bound toxins, has been proposed as a potential adjunctive therapy in cases of refractory vasodilatory shock associated with severe amlodipine poisoning. Methods: We report two cases of severe amlodipine poisoning complicated by refractory vasodilatory shock treated with the Molecular Adsorbent Recirculating System (MARS). A targeted PubMed search was also performed to identify published reports of calcium channel blocker intoxication with severe shock treated with MARS. Only reports describing amlodipine ingestion, either alone or with co-ingested agents, were included. Results: Both cases involved severe amlodipine poisoning complicated by refractory vasodilatory shock with multiorgan dysfunction requiring multiple vasopressors, high-dose insulin therapy, mechanical ventilation, and renal replacement therapy. Initiation of MARS was temporally associated with progressive hemodynamic stabilization, including reductions in vasopressor requirements and improvement in lactate levels. In the first case, MARS was successfully continued during prone ventilation for severe acute respiratory distress syndrome. In the second case, persistent cardiopulmonary failure required extracorporeal membrane oxygenation (ECMO). Reinitiation of MARS during ECMO support was associated with improved lactate clearance and reduced vasopressor requirements. Conclusions: Severe amlodipine poisoning can result in profound and persistent vasodilatory shock with multiorgan dysfunction despite multiple conventional and adjunctive therapies. MARS may represent a useful adjunctive therapy in selected cases and can be integrated into complex critical care strategies, including prone ventilation and extracorporeal membrane oxygenation.